WO2001072208A2 - Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle - Google Patents

Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle Download PDF

Info

Publication number
WO2001072208A2
WO2001072208A2 PCT/US2001/009884 US0109884W WO0172208A2 WO 2001072208 A2 WO2001072208 A2 WO 2001072208A2 US 0109884 W US0109884 W US 0109884W WO 0172208 A2 WO0172208 A2 WO 0172208A2
Authority
WO
WIPO (PCT)
Prior art keywords
episodes
hbaι
probability
category
estimated
Prior art date
Application number
PCT/US2001/009884
Other languages
English (en)
Other versions
WO2001072208A3 (fr
Inventor
Boris P. Kovatchev
Daniel J. Cox
Original Assignee
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22712035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001072208(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU5104601A priority Critical patent/AU5104601A/xx
Priority to PL357511A priority patent/PL198154B1/pl
Priority to CA002404262A priority patent/CA2404262C/fr
Priority to US10/240,228 priority patent/US7025425B2/en
Priority to IL15172001A priority patent/IL151720A0/xx
Priority to MXPA02009487A priority patent/MXPA02009487A/es
Priority to AU2001251046A priority patent/AU2001251046B2/en
Priority to EP01924388A priority patent/EP1267708A4/fr
Priority to DZ013338A priority patent/DZ3338A1/fr
Priority to JP2001570172A priority patent/JP4891511B2/ja
Application filed by University Of Virginia Patent Foundation filed Critical University Of Virginia Patent Foundation
Publication of WO2001072208A2 publication Critical patent/WO2001072208A2/fr
Publication of WO2001072208A3 publication Critical patent/WO2001072208A3/fr
Priority to IL151720A priority patent/IL151720A/en
Priority to US11/305,946 priority patent/US7874985B2/en
Priority to IL183273A priority patent/IL183273A0/en
Priority to US12/975,580 priority patent/US20120004512A1/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Definitions

  • the present system relates generally to Glycemic Control of individuals with diabetes, and more particularly to a computer-based system and method for evaluation of predicting glycosylated hemoglobin (HbA ⁇ c and HbA and risk of incurring hypoglycemia.
  • HbA ⁇ c and HbA glycosylated hemoglobin
  • hypoglycemia has been identified as a major barrier to improved glycemic control (Cryer PE: Hypoglycemia is the Limiting Factor in the Management Of Diabetes. Diabetes Metab Res Rev, 15: 42-46, 1999).
  • glycosylated hemoglobin is a marker for the glycemic control of individuals with Diabetes Mellitus (Type I or Type II). Numerous researchers have investigated this relationship and have found that glycosylated hemoglobin generally reflects the average BG levels of a patient over the previous two months. Since in the majority of patients with diabetes the BG levels fluctuate considerably over time, it was suggested that the real connection between integrated glucose control and HbA lc would be observed only in patients known to be in stable glucose control over a long period of time.
  • HbA lc was the "logical nominee" for a gold-standard glycosylated hemoglobin assay, and the DCCT established a linear relationship between the preceding mean BG and HbA ⁇ c (See Santiago JV (1993). Lessons from the Diabetes Control and Complications Trial, Diabetes. 42, 1549-1554). Guidelines were developed indicating that an HbA lc of 7% corresponds to a mean BG of 8.3 mM (150 mg/dl), an HbA ⁇ c of 9% corresponds to a mean BG of 11.7 mM (210 mg/dl), and a 1% increase in HbA lc corresponds to an increase in mean BG of 1.7 mM (30 mg/dl, 2).
  • the DCCT also suggested that because measuring the mean BG directly is not practical, one could assess a patient's glycemic control with a single, simple test, namely HbA lc . However, studies clearly demonstrate that HbA lc is not sensitive to hypoglycemia.
  • SMBG Self-Monitoring of BG
  • an object of this invention is to provide this missing link by proposing three distinct, but compatible, algorithms for evaluating HbA lc and the risk of hypoglycemia from SMBG data, to be used to predict the short-term and long-term risks of hypoglycemia, and the long-term risk of hyperglycemia.
  • the inventors have previously reported that one reason for a missing link between the routinely available SMBG data and the evaluation of HbA lc and the risk of hypoglycemia, is that the sophisticated methods of data collection and clinical assessment used in diabetes research, are infrequently supported by diabetes-specific and mathematically sophisticated statistical procedures.
  • BG levels are measured in mg/dl in the United States, and in mmol/L (or mM) in most other countries.
  • the entire BG range is given in most references as 1.1 to 33.3 mM, and this is considered to cover practically all observed values.
  • the target BG range - also known as the euglycemic range- for a person with diabetes is 3.9 to 10 mM
  • hypoglycemia occurs when the BG falls below 3.9 mM
  • hyperglycemia is when the BG rises above 10 mM.
  • the inventors introduced the Low BG Index - a new measure for assessing the risk of hypoglycemia from SMBG readings (See Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, Clarke WL: Frequency of Severe Hypoglycemia In IDDM Can Be Predicted From Self-Monitoring Blood Glucose Data. Journal of Clinical Endocrinology and Metabolism, 79: 1659-1662, 1994, and Kovatchev BP, Cox DJ, Gonder-Frederick LA Young-Hyman D, Schlundt D, Clarke WL.
  • HbA lc and SMBG See Kovatchev BP, Cox DJ, Straume M, Farhy LS. Association of Self-monitoring Blood Glucose Profiles with Glycosylated Hemoglobin. In: Methods in Enzymology, vol. 321 : Numerical Computer Methods. Part C. Michael Johnson and Ludvig Brand, Eds., Academic Press, NY; 2000).
  • the inventors have therefore sought to improve upon the aforementioned limitations associated with the conventional methods, and thereby provide simple and reliable methods that are capable of evaluating both patients' glycemic control and their risk of hypoglycemia, and that can be applied in their everyday environments.
  • the invention includes a data analysis method and computer-based system for the simultaneous evaluation, from routinely collected SMBG data, ofthe two most important components of glycemic control in diabetes: HbA lc and the risk of hypoglycemia.
  • SMBG self-monitoring of BG
  • this invention pertains directly to the enhancement of existing home blood glucose monitoring devices by introducing an intelligent data interpretation component capable of predicting both HbA ⁇ c and periods of increased risk of hypoglycemia, as well as to enhancement of future continuous monitoring devices by the same features.
  • One aspect ofthe invention includes a method, system, and computer program product for evaluating HbA lc from a predetermined period of collected SMBG data, for example 4-6 weeks.
  • the invention provides a computerized method and system for evaluating the HbA lc of a patient based on BG data collected over a predetermined duration.
  • the method includes computing weighted deviation toward high blood glucose (WR) and estimated rate of change of blood glucose (Dr) based on the collected BG data; estimating HbA ⁇ c using a predetermined mathematical formula based on the computed WR and Dr; and providing a predetermined confidence interval for classification of said estimated value of HbA lc .
  • Another aspect ofthe invention includes a method, system, and computer program product for estimating the long-term probability for severe hypoglycemia (SH).
  • This method uses SMBG readings from a predetermined period, for example 4- 6 weeks, and predicts the risk of SH within the following 6 months.
  • the invention provides a computerized method and system for evaluating the long term probability for severe hypoglycemia (SH) of a patient based on BG data collected over a predetermined duration.
  • the method includes: computing weighted deviation toward low blood glucose (WL) and estimated rate of fall of blood glucose in the low BG range (DrDn) based on the collected BG data; estimating the number of future SH episodes using a predetermined mathematical formula based on the computed WL and DrDn; and defining a probability of incurring a select number of SH episodes respective to said estimated SH episodes.
  • WL low blood glucose
  • DrDn estimated rate of fall of blood glucose in the low BG range
  • Still yet another aspect ofthe invention includes a method, system, and computer program product for identifying 24-hour periods (or other select periods) of increased risk of hypoglycemia. This is accomplished through the computation ofthe short-term risk of hypoglycemia using SMBG readings collected over the previous 24 hours.
  • the invention provides a computerized method and system for evaluating the short term risk for severe hypoglycemia (SH) of a patient based on BG data collected over a predetermined duration.
  • SH severe hypoglycemia
  • the method includes: computing weighted deviation toward low blood glucose (WL); determining Max(wl) by calculating maximum value o ⁇ wl(BG;2); determining risk value by taking the geometric mean of WL and Max(wl) over the predetermined duration; providing a predetermined threshold risk value; and comparing the determined risk value to the threshold risk value.
  • FIG. 1 is a flow chart illustrating the method of calculating the estimated HbA ⁇ c and predicted HbA lc confidence intervals in accordance with the present invention.
  • FIG. 2 is a flow chart illustrating the method of calculating the estimated number of future SH episodes and the associated probability thereof in accordance with the present invention.
  • FIG. 3 is a flow chart illustrating the method of calculating the estimated short term risk of an incurring imminent SH in accordance with the present invention.
  • FIG. 4 is graphical representation of a typical BG disturbances observed before and after an episode of severe hypoglycemia.
  • FIG. 5 illustrates the action ofthe method for predicting short-term SH by presenting 10 weeks of data for Subject A (upper panel) and Subject B (lower panel). SH episodes are marked by triangle; a black line presents the risk value. When the risk threshold is crossed, the method indicates a subsequent high-risk period (gray bar).
  • FIG. 6 is a functional block diagram for a computer system for implementation ofthe present invention.
  • FIGS. 7-9 are schematic block diagrams of alternative variations ofthe present invention related processors, communication links, and systems.
  • the invention makes possible, but not limited thereto, the creation of precise methods for the evaluation of diabetics' glycemic control, and include, firmware and software code to be used in computing the key components ofthe method.
  • the inventive methods for evaluating HbA lc , the long-term probability of SH, and the short-term risk of hypoglycemia, are also validated based on the extensive data collected, as will be discussed later in this document. Finally, the aspects of these methods can be combined in structured display or matrix. Stationary measures of BG deviation
  • ⁇ (towards hypoglycemia) or to the right (towards hyperglycemia) are computed.
  • the weighting parameter a and b could be different, or the same for the left and right deviations.
  • DrDn be the average ofthe numbers S k+ i - Sk, provided that C* e Mdn
  • Dr be the average ofthe numbers s k+ i - S , provided that e M up + M dminister.
  • DrDn and Dr provide a measure for the rate of change of BG in a "risk space," e.g. the rate of change ofthe risk associated with any BG level change.
  • DrDn measures the rate of BG change only when BG goes down, i.e. DrDn evaluates how quickly the risk could increase when BG falls, while Dr is a measure ofthe overall vulnerability of BG to fluctuations. It is further asserted that DrDn will be associated with risk for hypoglycemia (if someone's blood glucose could fall quickly, his/her risk for hypoglycemia would be higher), while Dr will be associated with the overall stability of BG.
  • the first is for when the BG readings are in mmol/L, and in this case the variable is BGMM.
  • the second is for when the BG readings are in mg/dl, and in this case the variable is BGMG.
  • each BG reading is first transformed as follows:
  • Dr mean ( Dr)
  • SMBG data is collected over a predetermined period of time.
  • the SMBG data is collected over 4-6 weeks with a frequency of 3-5 BG measurements per day, of which are transformed by the code or formulas presented in the previous section. Different formulas are to be used if the BG measurements are stored in mg/dl, or in mmol/1.
  • WR high blood glucose
  • Dr estimated rate of change of blood glucose
  • HbA lc estimate categories representing a range of values for estimated HbAi c are defined according to Table 1.
  • step 110 predicted confidence intervals for corresponding HbA ⁇ c are derived according to Table 2.
  • step 112 the estimated HbA ⁇ c from step 106 is assigned in one ofthe categories provided in Table 1 and / or Table 2.
  • SMBG data is collected over a predetermined period of time. For example, the SMBG data is collected over 4-6 weeks with a frequency of 3-5 BG measurements per day, of which are transformed by the code or formulas presented immediately above.
  • WL and DrDn are computed using the formula / code as discussed above.
  • an estimate ofthe number of future SH episodes is computed using the linear function:
  • EstNSH 3.3613*WL - 4.3427*DrDn - 1.2716. It is noted that the coefficients of this function are derived from data for 181 individuals with diabetes, and one would appreciate that further data accumulation may update these coefficients. It is further noted that this formula provides a single value estimate for the number of future SH episodes and that through additional methodologies, as discussed below, categories are provided with ranges and confidence levels for enhanced clinical applications. In step 208, estimated number of SH episodes (estNSH) categories representing a range of values for estNSH are defined according to Table 3.
  • step 210 respective to the estNSH categories, the probability of incurring 0, 1-2, or more than 2 SH episodes in the following six months is derived, as represented in table 4.
  • step 212 the EstNSH from step 206 is assigned in one of the categories provided in Table 3 and / or Table 4.
  • Empirical Validation of Evaluation ofthe Long-Term Probability for SH One-hundred-eighty-one adults with Type 1 diabetes used memory meters to collect more than 34,000 SMBG over a month. Then for the next six months they recorded in diaries any occurrence of SH.
  • BG as measured in "risk space” provide an accurate assessment ofthe long-term risk of SH. Because it is based on SMBG records that are automatically stored by many reflectance meters, this is an effective and clinically useful indicator of patients' glycemic control in the low BG range.
  • SMBG short term risk of SH evaluation method 300 according to the invention is illustrated in FIG. 3.
  • a first step 302 SMBG is data is collected over a predetermined short term period.
  • the SMBG data is collected over a 24 hour period, with a frequency of 3-5 BG measurements per day - 4 or more readings, as a nominal level according to data analyses.
  • a step 304 WL(24) and Max(wl) is computed from all readings collected within the preceding 24 hours, wherein the maximum value of wl(BG;2) is Max(wl).
  • the risk value is by taking the geometric mean of WL and Max(wl) over the 24 hour period, wherein said risk value is mathematically defined as:
  • a threshold risk value is determined.
  • the estimated risk value is compared to the threshold risk value. For example, if the threshold risk value is set at 17, then if Risk(24)> 17, then-based on the SMBG data collected over the previous 24 hours— the resultant indication is a high risk ofthe patient incurring imminent hypoglycemia. In other words, this is a decision-making rule that considers a 24-hour period of SMBG data and judges whether this period is likely to precede an imminent hypoglycemia episode.
  • the threshold value of 17 is derived from an extensive data set, however, it is recognized that it is possible that this value maybe adjusted with further accumulation of data or for additional objectives.
  • Empirical Validation of Evaluation ofthe Short-term Risk of Hypoglycemia Eighty-five individuals were recruited through advertisement in newsletters, diabetes clinics, and through direct referrals. The inclusion criteria were: 1) age of 21- 60 years; 2) type I diabetes with at least two years duration, and insulin use since the time of diagnosis; 3) at least 2 documented SH episodes in the past year; and 4) routine use of SMBG devices for diabetes monitoring. The participants were instructed to use the meter 3-5 times a day, and to record in monthly diaries any SH episodes, including the exact dates and times of their occurrences. SH was defined as severe neuroglycopenia that results in stupor or unconsciousness and precludes self-treatment.
  • FIG. 4 is graphical representation of a typical BG disturbance observed before and after an episode of severe hypoglycemia.
  • the average BG level decreased and the variance of BG increased.
  • the average BG level dropped further and the variance of BG continued to increase.
  • the average BG level normalized, but the BG variance remained greatly increased. Both the average BG and its variance returned to their baseline levels within 48 hours after the SH episode.
  • the disturbances presented in FIG. 4 are quantified from SMBG data to enable the evaluation ofthe short-term risk of hypoglycemia.
  • the inventors simulated the action ofthe short-term risk method on a 6-month series of SMBG readings for 85 individuals with Type I diabetes. With four or more SMBG readings per day, at least 50% of all episodes of SH could be anticipated. Even when symptomatic SH did not occur, the algorithm predicted episodes of moderate hypoglycemia.
  • the output for subject 1 (Ss 1) shown in the above grid indicates that this person is likely to have HbA ⁇ c between 9 and 9.5%, and has a 90% chance not to experience severe hypoglycemia in the subsequent 6 months.
  • the output for subject 2 (Ss 2) indicates that this person is likely to have HbA lc below 8%, and has a greater than 80% chance to experience at least 3 SH episodes in the subsequent 6 months.
  • the short term risk method provides a continuous tracking ofthe risk of imminent hypoglycemia and can be used to sound an alarm when this risk becomes high.
  • the method ofthe invention may be implemented using hardware, software or a combination thereof and may be implemented in one or more computer systems or other processing systems, such as personal digit assistants (PDAs).
  • PDAs personal digit assistants
  • the invention was implemented in software running on a general purpose computer 900 as illustrated in FIG. 6.
  • Computer system 600 includes one or more processors, such as processor 604.
  • Processor 604 is connected to a communication infrastructure 606 (e.g., a communications bus, cross-over bar, or network).
  • Computer system 600 includes a display interface 602 that forwards graphics, text, and other data from the communication infrastructure 606 (or from a frame buffer not shown) for display on the display unit 630.
  • Computer system 600 also includes a main memory 608, preferably random access memory (RAM), and may also include a secondary memory 610.
  • the secondary memory 610 may include, for example, a hard disk drive 612 and/or a removable storage drive 614, representing a floppy disk drive, a magnetic tape drive, an optical disk drive, etc.
  • the removable storage drive 614 reads from and/or writes to a removable storage unit 618 in a well known manner.
  • Removable storage unit 618 represents a floppy disk, magnetic tape, optical disk, etc. which is read by and written to by removable storage drive 614.
  • the removable storage unit 618 includes a computer usable storage medium having stored therein computer software and/or data.
  • secondary memory 610 may include other means for allowing computer programs or other instructions to be loaded into computer system 600.
  • Such means may include, for example, a removable storage unit 622 and an interface 620.
  • removable storage units/interfaces include a program cartridge and cartridge interface (such as that found in video game devices), a removable memory chip (such as a ROM, PROM, EPROM or EEPROM) and associated socket, and other removable storage units 622 and interfaces 620 which allow software and data to be transferred from the removable storage unit 622 to computer system 600.
  • Computer system 600 may also include a communications interface 624.
  • Communications interface 624 allows software and data to be transferred between computer system 600 and external devices. Examples of communications interface 624 may include a modem, a network interface (such as an Ethernet card), a communications port, a PCMCIA slot and card, etc.
  • Software and data transferred via communications interface 624 are in the form of signals 628 which may be electronic, electromagnetic, optical or other signals capable of being received by communications interface 624.
  • Signals 628 are provided to communications interface 624 via a communications path (i.e., channel) 626.
  • Channel 626 carries signals 628 and may be implemented using wire or cable, fiber optics, a phone line, a cellular phone link, an RF link and other communications channels.
  • computer program medium and “computer usable medium” are used to generally refer to media such as removable storage drive 914, a hard disk installed in hard disk drive 612, and signals 628.
  • These computer program products are means for providing software to computer system 600.
  • the invention includes such computer program products.
  • Computer programs are stored in main memory 608 and/or secondary memory 610. Computer programs may also be received via communications interface 624. Such computer programs, when executed, enable computer system 600 to perform the features ofthe present invention as discussed herein. In particular, the computer programs, when executed, enable processor 604 to perform the functions ofthe present invention. Accordingly, such computer programs represent controllers of computer system 600.
  • the software may be stored in a computer program product and loaded into computer system 600 using removable storage drive 614, hard drive 612 or communications interface 624.
  • the control logic when executed by the processor 604, causes the processor 604 to perform the functions ofthe invention as described herein.
  • the invention is implemented primarily in hardware using, for example, hardware components such as application specific integrated circuits (ASICs). Implementation ofthe hardware state machine to perform the functions described herein will be apparent to persons skilled in the relevant art(s).
  • the invention is implemented using a combination of both hardware and software.
  • the methods described above were implemented in SPSS control language, but could be implemented in other programs such as, but not limited to, C + + programming language.
  • FIGS. 7 - 9 show block diagrammatic representation of alternative embodiments ofthe invention.
  • a block diagrammatic representation ofthe system 710 essentially comprises the glucose meter 728 used by a patient 712 for recording, inter alia, insulin dosage readings and measured blood glucose (“BG") levels
  • Data obtained by the glucose meter 728 is preferably transferred through appropriate communication links 714 or data modem 732 to a processing station or chip, such as a personal computer 740, PDA, or cellular telephone.
  • a processing station or chip such as a personal computer 740, PDA, or cellular telephone.
  • data stored may be stored within the glucose meter 728 and may be directly downloaded into the personal computer 740 through an appropriate interface cable.
  • An example is the ONE TOUCH monitoring system or meter by LifeScan, Inc.
  • the glucose meter is common in the industry and includes essentially any device that can functions as a BG acquisition mechanism.
  • the BG meter or acquisition mechanism, device, tool, or system includes various conventional methods directed toward drawing a blood sample (e.g. by fingerprick) for each test, and a determination ofthe glucose level using an instrument that reads glucose concentrations by electromechanical or claorimetric methods.
  • various methods for determining the concentration of blood analytes without drawing blood have been developed.
  • U.S. Pat. No. 5,267,152 to Yang et al. describes a noninvasive technique of measuring blood glucose concentration using near-IR radiation diffuse-reflection laser spectroscopy. Similar near-IR spectrometric devices are also described in U.S. Pat. No. 5,086,229 to Rosenthal et al. and U.S. Pat. No. 4,975,581 to Robinson et al.
  • U.S. Pat. No. 5,139,023 to Stanley describes a transdermal blood glucose monitoring apparatus that relies on a permeability enhancer (e.g., a bile salt) to facilitate transdermal movement of glucose along a concentration gradient established between interstitial fluid and a receiving medium.
  • a permeability enhancer e.g., a bile salt
  • U.S. Pat. No. 5,036,861 to Sembrowich describes a passive glucose monitor that collects perspiration through a skin patch, where a cholinergic agent is used to stimulate perspiration secretion from the eccrine sweat gland. Similar perspiration collection devices are described in U.S. Pat. No. 5,076,273 to Schoendorfer and U.S. Pat. No. 5,140,985 to Schroeder.
  • U.S. Pat. No. 5,279,543 to Glikfeld describes the use of iontophoresis to noninvasively sample a substance through skin into a receptacle on the skin surface. Glikfeld teaches that this sampling procedure can be coupled with a glucose-specific biosensor or glucose-specific electrodes in order to monitor blood glucose.
  • International Publication No. WO 96/00110 to Tamada describes an iontophoretic apparatus for transdermal monitoring of a target substance, wherein an iontophoretic electrode is used to move an analyte into a collection reservoir and a biosensor is used to detect the target analyte present in the reservoir.
  • U.S. Pat. No. 6,144,869 to Berner describes a sampling system for measuring the concentration of an analyte present..
  • the BG meter or acquisition mechanism may include indwelling catheters and subcutaneous tissue fluid sampling.
  • the computer or PDA 740 includes the software and hardware necessary to process, analyze and interpret the self-recorded diabetes patient data in accordance with predefined flow sequences (as described above in detail) and generate an appropriate data interpretation output.
  • the results ofthe data analysis and interpretation performed upon the stored patient data by the computer 740 are displayed in the form of a paper report generated through a printer associated with the personal computer 740.
  • the results ofthe data interpretation procedure may be directly displayed on a video display unit associated with the computer 740.
  • FIG. 8 shows a block diagrammatic representation of an alternative embodiment having a diabetes management system that is a patient-operated apparatus 810 having a housing preferably sufficiently compact to enable apparatus 810 to be hand-held and carried by a patient.
  • a strip guide for receiving a blood glucose test strip (not shown) is located on a surface of housing 816.
  • Test strip is for receiving a blood sample from the patient 812.
  • the apparatus includes a microprocessor 822 and a memory 824 connected to microprocessor 822.
  • Microprocessor 22 is designed to execute a computer program stored in memory 824 to perform the various calculations and control functions as discussed in great detail above.
  • a keypad 816 is connected to microprocessor 822 through a standard keypad decoder 826.
  • Display 814 is connected to microprocessor 822 through a display driver 830.
  • Microprocessor 822 communicates with display driver 830 via an interface, and display driver 830 updates and refreshes display 814 under the control of microprocessor 822.
  • Speaker 854 and a clock 856 are also connected to microprocessor 822.
  • Speaker 854 operates under the control of microprocessor 822 to emit audible tones alerting the patient to possible future hypoglycemia.
  • Clock 856 supplies the current date and time to microprocessor 822.
  • Memory 824 also stores blood glucose values ofthe patient 812, the insulin dose values, the insulin types, and the parameter values used by microprocessor 822 to calculate future blood glucose values, supplemental insulin doses, and carbohydrate supplements. Each blood glucose value and insulin dose value is stored in memory 824 with a corresponding date and time. Memory 824 is preferably a non- volatile memory, such as an electrically erasable read only memory (EEPROM).
  • EEPROM electrically erasable read only memory
  • Apparatus 810 also includes a blood glucose meter 828 connected to microprocessor 822.
  • Glucose meter 828 is designed to measure blood samples received on blood glucose test strips and to produce blood glucose values from measurements of the blood samples. As mentioned previously, such glucose meters are well known in the art. Glucose meter 828 is preferably ofthe type which produces digital values which are output directly to microprocessor 822. Alternatively, blood glucose meter 828 may be ofthe type which produces analog values. In this alternative embodiment, blood glucose meter 828 is connected to microprocessor 822 through an analog to digital converter (not shown).
  • Apparatus 810 further includes an input/output port 834, preferably a serial port, which is connected to microprocessor 822.
  • Port 834 is connected to a modem 832 by an interface, preferably a standard RS232 interface.
  • Modem 832 is for establishing a communication link between apparatus 810 and a personal computer 840 or a healthcare provider computer 838 through a communication network 836.
  • Specific techniques for connecting electronic devices through connection cords are well known in the art.
  • Another alternative example is "bluetooth" technology communication.
  • FIG. 9 shows a block diagrammatic representation of an alternative embodiment having a diabetes management system that is a patient- operated apparatus 910, similar as shown in FIG. 8, having a housing preferably sufficiently compact to enable the apparatus 910 to be hand-held and carried by a patient.
  • the present embodiment includes a separate or detachable glucose meter or BG acquisition mechanism 928.
  • the embodiments described herein are capable of being implemented over data communication networks such as the internet, making evaluations, estimates, and information accessible to any processor or computer at any remote location, as depicted in FIGS. 6-9 and/or U.S. Pat. No. 5,851 , 186 to Wood, of which is hereby incorporated by reference herein.
  • patients located at remote locations may have the BG data transmitted to a central healthcare provider or residence, or a different remote location.
  • the invention proposes a data analysis computerized method and system for the simultaneous evaluation of the two most important components of glycemic control in individuals with diabetes: HbA ⁇ c and the risk of hypoglycemia.
  • the method while using only routine SMBG data, provides, among other things, three sets of output.
  • the invention enhances existing home BG monitoring devices by producing and displaying: 1) estimated categories for HbA lc , 2) estimated probability for SH in the subsequent six months, and 3) estimated short-term risk of hypoglycemia (i.e. for the next 24 hours).
  • the latter may include warnings, such as an alarm, that indicates imminent hypoglycemic episodes.
  • These three components can also be integrated to provide continuous information about the glycemic control of individuals with diabetes, and to enhance the monitoring of their risk of hypoglycemia.
  • the invention enhances existing software or hardware that retrieves SMBG data.
  • Such software or hardware is produced by virtually every manufacturer of home BG monitoring devices and is customarily used by patients and health care providers to interpret SMBG data.
  • the methods and system ofthe invention can be directly incorporated into existing home blood glucose monitors, or used for the enhancement of software that retrieves SMBG data, by introducing a data interpretation component capable of predicting both HbA ⁇ c and periods of increased risk of hypoglycemia.
  • the invention evaluates the accuracy of home BG monitoring devices, both in the low and high BG ranges, and over the entire BG scale. Moreover, another advantage, the invention evaluates the effectiveness of various treatments for diabetes.
  • the present invention alleviates this related problem by use of its simple and reliable methods, i.e., the invention is capable of evaluating both patients' glycemic control and their risk of hypoglycemia, and at the same time applying it in their everyday environments.
  • the invention provides the missing link by proposing three distinct, but compatible, algorithms for evaluating HbA lc and the risk of hypoglycemia from SMBG data, to be used to predict the short-term and long-term risks of hypoglycemia, and the long-term risk of hyperglycemia.
  • the invention evaluates the effectiveness of new insulin or insulin delivery devices. Any manufacturer or researcher of insulin or insulin delivery devices can utilize the embodiments ofthe invention to test the relative success of proposed or tested insulin types or device delivery designs.

Abstract

L'invention porte sur un procédé, un système, et un produit informatique relatifs au diagnostic du diabète et permettant de prédire chez les diabétiques les risques à long terme d'hyperglycémie, et les risques à long et court terme hypoglycémie sévère, recourant à des mesures du glucose sanguin fournies par un dispositif personnel d'auto-contrôle du glucose sanguin. Le procédé le système et le programme informatique ont directement trait à l'amélioration des glucomètres domestiques existants auxquels est ajouté un composant intelligent d'interprétation des résultats pouvant prévoir l'HbA1c et les périodes de risque accru d'hypoglycémie, et à l'amélioration des récents dispositifs de contrôle continu par ces mêmes moyens. Ces prévisions permettent aux diabétiques de prendre des mesures pour prévenir les conséquences adverses liées à l'hyperglycémie et à l'hypoglycémie.
PCT/US2001/009884 2000-03-29 2001-03-29 Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle WO2001072208A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP01924388A EP1267708A4 (fr) 2000-03-29 2001-03-29 Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle
JP2001570172A JP4891511B2 (ja) 2000-03-29 2001-03-29 自己モニタリングデータから糖尿病の血糖管理を評価する方法、システム及びコンピユータプログラム製品
DZ013338A DZ3338A1 (fr) 2000-03-29 2001-03-29 Méthode, systeme et programme d'ordinateur pour l'évaluation de régulation de glycemique du diabète à partir de données contrôllées automatiquement
US10/240,228 US7025425B2 (en) 2000-03-29 2001-03-29 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
PL357511A PL198154B1 (pl) 2000-03-29 2001-03-29 Sposób kontroli HbA₁c pacjenta w oparciu o dane stężenia glukozy we krwi, sposób oceny hipoglikemii u pacjenta i urządzenie do kontroli cukrzycy u pacjenta
MXPA02009487A MXPA02009487A (es) 2000-03-29 2001-03-29 Metodo, sistema y producto de programa de computadora para la evaluacion del control glucemico en la diabetes a partir de datos de auto-monitoreo.
AU2001251046A AU2001251046B2 (en) 2000-03-29 2001-03-29 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
AU5104601A AU5104601A (en) 2000-03-29 2001-03-29 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
CA002404262A CA2404262C (fr) 2000-03-29 2001-03-29 Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle
IL15172001A IL151720A0 (en) 2000-03-29 2001-03-29 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
IL151720A IL151720A (en) 2000-03-29 2002-09-12 Method and system and product Computer program for the evaluation of diabetes sugar control from data obtained from independent monitoring
US11/305,946 US7874985B2 (en) 2000-03-29 2005-12-19 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
IL183273A IL183273A0 (en) 2000-03-29 2007-05-17 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US12/975,580 US20120004512A1 (en) 2000-03-29 2010-12-22 Method, System, and Computer Program Product For The Evaluation of Glycemic Control in Diabetes From Self-Monitoring Data

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19303700P 2000-03-29 2000-03-29
US60/193,037 2000-03-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10240228 A-371-Of-International 2001-03-29
US11/305,946 Division US7874985B2 (en) 2000-03-29 2005-12-19 Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data

Publications (2)

Publication Number Publication Date
WO2001072208A2 true WO2001072208A2 (fr) 2001-10-04
WO2001072208A3 WO2001072208A3 (fr) 2002-03-07

Family

ID=22712035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009884 WO2001072208A2 (fr) 2000-03-29 2001-03-29 Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle

Country Status (13)

Country Link
US (3) US7025425B2 (fr)
EP (1) EP1267708A4 (fr)
JP (1) JP4891511B2 (fr)
KR (1) KR100776070B1 (fr)
CN (1) CN100448392C (fr)
AU (2) AU5104601A (fr)
CA (1) CA2404262C (fr)
DZ (1) DZ3338A1 (fr)
IL (3) IL151720A0 (fr)
MX (1) MXPA02009487A (fr)
PL (1) PL198154B1 (fr)
RU (1) RU2283495C2 (fr)
WO (1) WO2001072208A2 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065033A2 (fr) * 2002-01-28 2003-08-07 Control Diabetes, Inc. Procedes et systemes permettant d'evaluer le controle de glycemie par une analyse d'une etiquette de schema predeterminee des valeurs mesurees de glycemie
WO2004015539A2 (fr) 2002-08-13 2004-02-19 University Of Virginia Patent Foundation Procede, systeme et produit de programme informatique pour le traitement de donnees d'autosurveillance de glycemie (smbg) permettant d'ameliorer une autogestion diabetique
EP1416417A2 (fr) * 2002-10-08 2004-05-06 Bayer Healthcare, LLC Procédé et systèmes pour le traitement de données de diagnostic et de traitement de patients
WO2006050980A2 (fr) * 2004-11-15 2006-05-18 Novo Nordisk A/S Procede et appareil permettant de surveiller des effets a long et court termes d'un traitement
WO2007081853A2 (fr) 2006-01-05 2007-07-19 University Of Virginia Patent Foundation Méthode, système et programme informatique d’évaluation des variations de la glycémie chez les diabétiques, à partir de donné d'auto-contrôle
US7266400B2 (en) 2003-05-06 2007-09-04 Orsense Ltd. Glucose level control method and system
EP1956371A2 (fr) 2006-12-21 2008-08-13 Lifescan, Inc. Systèmes, procédés et codes de programme informatique pour reconnaissance de motifs d'hyperglycémie et d'hypoglycémie, variabilité de glucose augmentée, et auto-surveillance inefficace pour les diabètes
WO2010077330A1 (fr) * 2008-12-31 2010-07-08 Medtronic Minimed, Inc. Procédé et/ou système d'estimation du taux d'hémoglobine glyquée
EP2218394A1 (fr) * 2009-02-17 2010-08-18 Clifton A. Alferness Système et procédé pour fournir un outil personnalisé pour évaluer l'hémoglobine glyquée
US7815569B2 (en) 2004-04-21 2010-10-19 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
US7824333B2 (en) 2006-03-31 2010-11-02 Lifescan, Inc. Diabetes management methods and systems
US7914449B2 (en) 2004-03-17 2011-03-29 Sysmex Corporation Diagnostic support system for diabetes and storage medium
WO2013073983A1 (fr) * 2011-11-16 2013-05-23 Vengerov Yury Yuzefovitch Dispositif de lecture de résultats d'analyses réalisées à l'aide d'une languette de test
US8744828B2 (en) 2012-07-26 2014-06-03 Rimidi Diabetes, Inc. Computer-implemented system and method for improving glucose management through modeling of circadian profiles
US8756043B2 (en) 2012-07-26 2014-06-17 Rimidi Diabetes, Inc. Blood glucose meter and computer-implemented method for improving glucose management through modeling of circadian profiles
US8768673B2 (en) 2012-07-26 2014-07-01 Rimidi Diabetes, Inc. Computer-implemented system and method for improving glucose management through cloud-based modeling of circadian profiles
CN104470430A (zh) * 2012-07-19 2015-03-25 生命扫描有限公司 指示糖尿病人群高血糖或低血糖的方法和系统
WO2016093684A1 (fr) * 2014-12-09 2016-06-16 Instituto Superior Autónomo De Occidente A.C. Appareil électronique portable émettant des suggestions sur des activités ou des événements influençant un état d'intérêt pour un individu
US9501949B2 (en) 2004-10-07 2016-11-22 Novo Nordisk A/S Method and system for self-management of a disease
US10420489B2 (en) 2009-05-29 2019-09-24 University Of Virginia Patent Foundation System coordinator and modular architecture for open-loop and closed-loop control of diabetes
US10463789B2 (en) 2015-09-02 2019-11-05 University Of Virginia Patent Foundation System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users
US10524669B2 (en) 2003-10-13 2020-01-07 Novo Nordisk A/S Apparatus and method for determining a physiological condition
EP3593711A1 (fr) 2010-03-26 2020-01-15 The University of Virginia Patent Foundation Procédé, système et produit-programme d'ordinateur permettant d'améliorer la précision des capteurs de glucose utilisant l'observation de la délivrance d'insuline dans le diabète
US10610154B2 (en) 2011-06-23 2020-04-07 University Of Virginia Patent Foundation Unified platform for monitoring and control of blood glucose levels in diabetic patients
US10881334B2 (en) 2014-08-14 2021-01-05 University Of Virginia Patent Foundation Accuracy continuous glucose monitoring method, system, and device
US20210038132A1 (en) * 2009-02-25 2021-02-11 University Of Virginia Patent Foundation Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery
EP3799073A1 (fr) 2011-08-26 2021-03-31 The University of Virginia Patent Foundation Procédé, système et support lisible par ordinateur pour la régulation adaptative conseillée du diabète
RU2746830C1 (ru) * 2020-06-01 2021-04-21 Федеральное государственное бюджетное научное учреждение Федеральный исследовательский центр "Институт цитологии и генетики Сибирского отделения Российской академии наук" (ИЦиГ СО РАН) Способ оценки вариабельности гликемии для определения эффективности проводимой сахароснижающей терапии у пациентов с MODY2 диабетом
US11311665B2 (en) 2015-06-09 2022-04-26 University Of Virginia Patent Foundation Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking
WO2022199765A1 (fr) * 2021-03-22 2022-09-29 Eyesense Gmbh Procédé pour déterminer une valeur instantanée de glucose dans un fluide de transport

Families Citing this family (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
CA2352295C (fr) * 1998-11-30 2008-07-15 Novo Nordisk A/S Procede et systeme permettant a un utilisateur de s'administrer seul son traitement medical, ledit traitement medical comprenant plusieurs actes
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
JP4498636B2 (ja) 2001-04-27 2010-07-07 日本サーモスタット株式会社 サーモスタット装置
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
AU2002348683A1 (en) 2001-06-12 2002-12-23 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
WO2002100460A2 (fr) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Actionneur electrique de lancette
ES2357887T3 (es) 2001-06-12 2011-05-03 Pelikan Technologies Inc. Aparato para mejorar la tasa de éxito de obtención de sangre a partir de una punción capilar.
EP1404232B1 (fr) 2001-06-12 2009-12-02 Pelikan Technologies Inc. Appareil de prelevement sanguin et procede connexe
JP2004538078A (ja) * 2001-08-20 2004-12-24 インバネス・メディカル・リミテッド 無線糖尿病管理装置および無線糖尿病管理装置の使用方法
ATE520362T1 (de) 2001-12-03 2011-09-15 Ekos Corp Katheter mit mehreren ultraschall-abstrahlenden teilen
US8858434B2 (en) 2004-07-13 2014-10-14 Dexcom, Inc. Transcutaneous analyte sensor
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
JP4289869B2 (ja) * 2002-11-06 2009-07-01 シスメックス株式会社 糖尿病診断支援システム
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
WO2006001797A1 (fr) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Element penetrant peu douloureux
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US20070208245A1 (en) * 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US20100168657A1 (en) 2003-08-01 2010-07-01 Dexcom, Inc. System and methods for processing analyte sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7959569B2 (en) 2003-08-01 2011-06-14 Dexcom, Inc. System and methods for processing analyte sensor data
US6931327B2 (en) 2003-08-01 2005-08-16 Dexcom, Inc. System and methods for processing analyte sensor data
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
WO2005033659A2 (fr) 2003-09-29 2005-04-14 Pelikan Technologies, Inc. Procede et appareil permettant d'obtenir un dispositif de capture d'echantillons ameliore
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
WO2005041103A2 (fr) * 2003-10-29 2005-05-06 Novo Nordisk A/S Système de consultation médicale
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
EP1711790B1 (fr) 2003-12-05 2010-09-08 DexCom, Inc. Techniques d'etalonnage pour un capteur de substances a analyser en continu
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
EP1711791B1 (fr) 2003-12-09 2014-10-15 DexCom, Inc. Traitement de signal pour capteur continu d'analyte
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
WO2005089103A2 (fr) 2004-02-17 2005-09-29 Therasense, Inc. Procede et systeme de communication de donnees dans un systeme de controle et de gestion de glucose en continu
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
SE0400456D0 (sv) * 2004-02-26 2004-02-26 Lars Liljeryd Multiparameter metabolic monitoring, a method and device for the improvement of management and control in borderline or manifest type 2-diabetes
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
EP1765194A4 (fr) 2004-06-03 2010-09-29 Pelikan Technologies Inc Procede et appareil pour la fabrication d'un dispositif d'echantillonnage de liquides
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US7905833B2 (en) 2004-07-13 2011-03-15 Dexcom, Inc. Transcutaneous analyte sensor
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
ITBO20050002A1 (it) * 2005-01-04 2006-07-05 Giacomo Vespasiani Metodo e sistema per la gestione interattiva di dati relativi ad una terapia insulinica in autocontrollo per un paziente diabetico
US7798961B1 (en) 2005-01-11 2010-09-21 BeWell Mobile Technology Inc. Acquisition and management of time dependent health information
US20090312620A1 (en) * 2005-04-27 2009-12-17 Hou-Mei Henry Chang Diabetes monitor
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
AU2006254849A1 (en) * 2005-06-08 2006-12-14 Agamatrix, Inc. Data collection system and interface
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US20090227855A1 (en) 2005-08-16 2009-09-10 Medtronic Minimed, Inc. Controller device for an infusion pump
US7737581B2 (en) 2005-08-16 2010-06-15 Medtronic Minimed, Inc. Method and apparatus for predicting end of battery life
US20080314395A1 (en) 2005-08-31 2008-12-25 Theuniversity Of Virginia Patent Foundation Accuracy of Continuous Glucose Sensors
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8192394B2 (en) * 2005-11-08 2012-06-05 Asante Solutions, Inc. Method and system for manual and autonomous control of an infusion pump
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
EP1991110B1 (fr) 2006-03-09 2018-11-07 DexCom, Inc. Systèmes et procédés de traitement de données de capteur de substance à analyser
EP1839566A1 (fr) * 2006-03-29 2007-10-03 F. Hoffmann-La Roche AG Procédé et assemblage de surveillance d'un dispositif médical.
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
BRPI0711433A2 (pt) * 2006-05-08 2011-11-16 Bayer Healthcare Llc sistema de detecção de saìda anormal para um biosensor
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
WO2008009737A2 (fr) * 2006-07-19 2008-01-24 Cross Technology Solutions Ab Appareil mobile, procédé et système de traitement de facteurs affectant la glycémie
US8135548B2 (en) 2006-10-26 2012-03-13 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8439837B2 (en) * 2006-10-31 2013-05-14 Lifescan, Inc. Systems and methods for detecting hypoglycemic events having a reduced incidence of false alarms
US20080306353A1 (en) * 2006-11-03 2008-12-11 Douglas Joel S Calculation device for metabolic control of critically ill and/or diabetic patients
US8079955B2 (en) * 2006-11-28 2011-12-20 Isense Corporation Method and apparatus for managing glucose control
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
US20080199894A1 (en) 2007-02-15 2008-08-21 Abbott Diabetes Care, Inc. Device and method for automatic data acquisition and/or detection
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
EP2146624B1 (fr) 2007-04-14 2020-03-25 Abbott Diabetes Care Inc. Procédé et appareil pour réaliser le traitement et la commande de données dans un système de communication médical
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683721C (fr) 2007-04-14 2017-05-23 Abbott Diabetes Care Inc. Procede et appareil pour assurer une amplification de signal dynamique a etapes multiples dans un dispositif medical
EP2146625B1 (fr) 2007-04-14 2019-08-14 Abbott Diabetes Care Inc. Procédé et appareil pour réaliser le traitement et la commande de données dans un système de communication médical
CA2683930A1 (fr) 2007-04-14 2008-10-23 Abbott Diabetes Care Inc. Procede et appareil pour realiser le traitement et la commande de donnees dans un systeme de communication medical
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2008144616A1 (fr) * 2007-05-18 2008-11-27 Heidi Kay Composés assurant la modulation des radeaux lipidiques, des protéines que sont les cavéolines et des fonctions cavéolaires, et procédés de synthèse et thérapeutiques associés
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
US20080306434A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20080311968A1 (en) * 2007-06-13 2008-12-18 Hunter Thomas C Method for improving self-management of a disease
DK2006786T3 (en) * 2007-06-18 2018-08-06 Hoffmann La Roche Method and glucose monitoring system to monitor individual metabolic response and to generate nutrient feedback
EP3533387A3 (fr) 2007-06-21 2019-11-13 Abbott Diabetes Care, Inc. Dispositifs et procédés de gestion de la santé
AU2008265542B2 (en) 2007-06-21 2014-07-24 Abbott Diabetes Care Inc. Health monitor
EP2494932B1 (fr) 2007-06-22 2020-05-20 Ekos Corporation Appareil pour le traitement des hémorragies intracrâniennes
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US20090143725A1 (en) * 2007-08-31 2009-06-04 Abbott Diabetes Care, Inc. Method of Optimizing Efficacy of Therapeutic Agent
EP4159114B1 (fr) 2007-10-09 2024-04-10 DexCom, Inc. Système d'administration d'insuline intégré avec un capteur de glucose en continu
US7731659B2 (en) * 2007-10-18 2010-06-08 Lifescan Scotland Limited Method for predicting a user's future glycemic state
US7695434B2 (en) * 2007-10-19 2010-04-13 Lifescan Scotland, Ltd. Medical device for predicting a user's future glycemic state
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US20110077930A1 (en) * 2008-02-12 2011-03-31 Alferness Clifton A Computer-implemented method for providing a personalized tool for estimating 1,5-anhydroglucitol
US20100138453A1 (en) * 2008-02-12 2010-06-03 Alferness Clifton A System and method for generating a personalized diabetes management tool for diabetes mellitus
US20100198021A1 (en) * 2008-02-12 2010-08-05 Alferness Clifton A Computer-implemented method for providing a tunable personalized tool for estimating glycated hemoglobin
US20100198020A1 (en) * 2008-02-12 2010-08-05 Alferness Clifton A System And Method For Computer-Implemented Method For Actively Managing Increased Insulin Resistance In Type 2 Diabetes Mellitus
US20100138203A1 (en) * 2008-02-12 2010-06-03 Alferness Clifton A System and method for actively managing type 2 diabetes mellitus on a personalized basis
US20100145173A1 (en) * 2008-02-12 2010-06-10 Alferness Clifton A System and method for creating a personalized tool predicting a time course of blood glucose affect in diabetes mellitus
US20100145670A1 (en) * 2008-02-12 2010-06-10 Alferness Clifton A System and method for managing type 2 diabetes mellitus through a personal predictive management tool
US20100137786A1 (en) * 2008-02-12 2010-06-03 Alferness Clifton A System and method for actively managing type 1 diabetes mellitus on a personalized basis
US20100145725A1 (en) * 2008-02-12 2010-06-10 Alferness Clifton A System and method for managing type 1 diabetes mellitus through a personal predictive management tool
CA2715628A1 (fr) 2008-02-21 2009-08-27 Dexcom, Inc. Systemes et procedes pour traiter, transmettre et afficher des donnees de detecteur
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US10624577B2 (en) 2008-04-04 2020-04-21 Hygieia, Inc. Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
US9220456B2 (en) 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
EP2260423B1 (fr) * 2008-04-04 2018-02-28 Hygieia, Inc. Appareil pour optimiser un régime posologique d'insuline d'un patient
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
CN101261276B (zh) * 2008-04-17 2012-04-18 北京软测科技有限公司 糖尿病监测及诊治装置
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
WO2010009172A1 (fr) 2008-07-14 2010-01-21 Abbott Diabetes Care Inc. Interface de système de commande en boucle fermée et procédés
US8762306B2 (en) * 2008-08-14 2014-06-24 The University Of Toledo Neural network for glucose therapy recommendation
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US8992464B2 (en) 2008-11-11 2015-03-31 Hygieia, Inc. Apparatus and system for diabetes management
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US20100198034A1 (en) 2009-02-03 2010-08-05 Abbott Diabetes Care Inc. Compact On-Body Physiological Monitoring Devices and Methods Thereof
US8882678B2 (en) * 2009-03-13 2014-11-11 Atrium Medical Corporation Pleural drainage system and method of use
US9446194B2 (en) 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
EP2419015A4 (fr) 2009-04-16 2014-08-20 Abbott Diabetes Care Inc Gestion d'étalonnage de capteur d'analyte
WO2010127050A1 (fr) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Détection d'erreur dans des données de répétition critiques dans un système de capteur sans fil
WO2010127187A1 (fr) 2009-04-29 2010-11-04 Abbott Diabetes Care Inc. Procédé et système assurant une communication de données dans la surveillance du glucose en continu et système de gestion
EP2425209A4 (fr) 2009-04-29 2013-01-09 Abbott Diabetes Care Inc Procédé et système pour fournir un étalonnage de détecteur d'analyte en temps réel avec remplissage rétrospectif
WO2010132447A2 (fr) 2009-05-11 2010-11-18 Diabetomics, Llc Procédés pour détecter un prédiabète et un diabète à l'aide de la glycosylation différentielle de protéines
WO2010138856A1 (fr) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Systèmes d'antenne de dispositif médical comportant des configurations d'antenne externe
US20100330598A1 (en) * 2009-06-26 2010-12-30 Roche Diagnostics Operations, Inc. METHOD, SYSTEM, AND COMPUTER PROGRAM PRODUCT FOR PROVIDING BOTH AN ESTIMATED TRUE MEAN BLOOD GLUCOSE VALUE AND ESTIMATED GLYCATED HEMOGLOBIN (HbA1C) VALUE FROM STRUCTURED SPOT MEASUREMENTS OF BLOOD GLUCOSE
EP2455877A3 (fr) * 2009-06-30 2013-01-02 Lifescan Scotland Limited Procédé de gestion de diabète
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
DK3689237T3 (da) 2009-07-23 2021-08-16 Abbott Diabetes Care Inc Fremgangsmåde til fremstilling og system til kontinuerlig analytmåling
WO2011014851A1 (fr) 2009-07-31 2011-02-03 Abbott Diabetes Care Inc. Procédé et appareil pour apporter une précision de calibration d'un système de surveillance d'analyte
WO2011018465A1 (fr) 2009-08-10 2011-02-17 Diabetes Tools Sweden Ab Appareil et procédé permettant de traiter un ensemble de valeurs de données
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
EP3001194B1 (fr) 2009-08-31 2019-04-17 Abbott Diabetes Care, Inc. Dispositifs médicaux et procédés
ES2959131T3 (es) 2009-08-31 2024-02-20 Abbott Diabetes Care Inc Visualizadores para un dispositivo médico
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
CN102770761A (zh) 2009-09-02 2012-11-07 弗吉尼亚大学专利基金会 从自我监测血糖(smbg)数据追踪糖尿病中即将发生低血糖的概率
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US20110092788A1 (en) * 2009-10-15 2011-04-21 Roche Diagnostics Operations, Inc. Systems And Methods For Providing Guidance In Administration Of A Medicine
WO2011053881A1 (fr) 2009-10-30 2011-05-05 Abbott Diabetes Care Inc. Méthode et appareil pour détecter de faux états hypoglycémiques
US20110163880A1 (en) * 2010-01-07 2011-07-07 Lisa Halff System and method responsive to an alarm event detected at an insulin delivery device
US8803688B2 (en) * 2010-01-07 2014-08-12 Lisa Halff System and method responsive to an event detected at a glucose monitoring device
US20110184265A1 (en) * 2010-01-22 2011-07-28 Abbott Diabetes Care Inc. Method and Apparatus for Providing Notification in Analyte Monitoring Systems
WO2011112753A1 (fr) 2010-03-10 2011-09-15 Abbott Diabetes Care Inc. Systèmes, dispositifs et procédés pour le contrôle de niveaux de glucose
CA2792758C (fr) * 2010-03-11 2020-12-15 University Of Virginia Patent Foundation Procede et systeme pour la surete, l'analyse et la supervision de l'action d'une pompe a insuline et d'autres modes d'administration de l'insuline dans des cas de diabete
KR101100987B1 (ko) * 2010-03-23 2011-12-30 삼성모바일디스플레이주식회사 터치 스크린 패널
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
JP6291253B2 (ja) 2010-08-27 2018-03-14 イーコス・コーポレイシヨン 超音波カテーテル
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
EP2491859A1 (fr) * 2011-02-23 2012-08-29 F. Hoffmann-La Roche AG Procédé et système permettant de déterminer les caractéristiques de glucose sanguin à partir d'un mode discontinu de mesure et produit de programme informatique
CN107019515B (zh) 2011-02-28 2021-02-26 雅培糖尿病护理公司 显示传感器读数的方法与分析物监测装置及其操作方法
KR20120116581A (ko) * 2011-04-13 2012-10-23 주식회사 필로시스 만보기 기능을 가지는 혈당측정기를 이용한 운동량 제어방법
WO2012142502A2 (fr) 2011-04-15 2012-10-18 Dexcom Inc. Étalonnage avancé de capteur d'échantillon à analyser et détection d'erreur avancée
CN103959291B (zh) * 2011-04-20 2018-05-11 诺沃—诺迪斯克有限公司 基于具有自适应选择的核和正则化参数的正则化网络的葡萄糖预测器
JP5997453B2 (ja) * 2011-04-25 2016-09-28 アークレイ株式会社 情報処理装置およびユーザ端末
US20130035865A1 (en) 2011-08-05 2013-02-07 Dexcom, Inc. Systems and methods for detecting glucose level data patterns
US10434325B2 (en) * 2011-09-08 2019-10-08 Johnson & Johnson Consumer Inc. Light therapy platform mobile device applications
WO2013066849A1 (fr) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Mécanisme de prévention de fausse alarme de seuil de glucose à risque variable basé sur un modèle
US9069536B2 (en) 2011-10-31 2015-06-30 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
AU2012335830B2 (en) 2011-11-07 2017-05-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
WO2013078426A2 (fr) 2011-11-25 2013-05-30 Abbott Diabetes Care Inc. Système de surveillance des analytes et ses procédés d'utilisation
US9433376B2 (en) 2012-03-16 2016-09-06 Dexcom, Inc. Systems and methods for processing analyte sensor data
US20140030748A1 (en) * 2012-07-27 2014-01-30 Lifescan, Inc. Method and system to manage diabetes using multiple risk indicators for a person with diabetes
EP3395252A1 (fr) 2012-08-30 2018-10-31 Abbott Diabetes Care, Inc. Détection de pertes d'information dans des données de surveillance continue d'analyte lors d'excursions des données
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
USD688907S1 (en) 2012-09-20 2013-09-03 Steelcase Inc. Arm assembly
USD694539S1 (en) 2012-09-20 2013-12-03 Steelcase Inc. Chair
USD697727S1 (en) 2012-09-20 2014-01-21 Steeelcase Inc. Chair
US8998339B2 (en) 2012-09-20 2015-04-07 Steelcase Inc. Chair assembly with upholstery covering
USD694537S1 (en) 2012-09-20 2013-12-03 Steelcase Inc. Chair
USD697729S1 (en) 2012-09-20 2014-01-21 Steelcase Inc. Chair
US11304528B2 (en) 2012-09-20 2022-04-19 Steelcase Inc. Chair assembly with upholstery covering
USD699061S1 (en) 2012-09-20 2014-02-11 Steelcase Inc. Arm assembly
USD683151S1 (en) 2012-09-20 2013-05-28 Steelcase Inc. Chair
USD694538S1 (en) 2012-09-20 2013-12-03 Steelcase Inc. Chair
USD697726S1 (en) 2012-09-20 2014-01-21 Steelcase Inc. Chair
US11229294B2 (en) 2012-09-20 2022-01-25 Steelcase Inc. Chair assembly with upholstery covering
USD942767S1 (en) 2012-09-20 2022-02-08 Steelcase Inc. Chair assembly
EP2901153A4 (fr) 2012-09-26 2016-04-27 Abbott Diabetes Care Inc Procédé et appareil d'amélioration de correction de retard pendant une mesure in vivo de concentration de substance à analyser avec des données de variabilité et de plage de concentration de substance à analyser
WO2014055718A1 (fr) 2012-10-04 2014-04-10 Aptima, Inc. Systèmes et procédés de soutien clinique
US10463282B2 (en) * 2012-10-04 2019-11-05 Roche Diabetes Care, Inc. System and method for assessing risk associated with a glucose state
JP5511033B1 (ja) * 2012-12-04 2014-06-04 Ｎｅｃシステムテクノロジー株式会社 血糖値予測装置、測定装置、血糖値予測方法、及びプログラム
RU2640172C2 (ru) 2013-02-21 2017-12-26 Университи Оф Вирджиния Патент Фоундэйшион Отслеживание изменений усредненных значений гликемии у диабетиков
SG11201506154RA (en) 2013-03-14 2015-09-29 Ekos Corp Method and apparatus for drug delivery to a target site
US10335075B2 (en) * 2013-03-14 2019-07-02 Dexcom, Inc. Advanced calibration for analyte sensors
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
WO2014152034A1 (fr) 2013-03-15 2014-09-25 Abbott Diabetes Care Inc. Détection de défaut de capteur utilisant une comparaison de structures de données de capteur d'analyte
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US20150095042A1 (en) * 2013-09-27 2015-04-02 Roche Diagnostics Operations, Inc. High/low blood glucose risk assessment systems and methods
WO2015102745A1 (fr) 2013-12-31 2015-07-09 Abbott Diabetes Care Inc. Capteur d'analytes auto-alimenté et dispositifs utilisant ce dernier
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
EP3125761B1 (fr) 2014-03-30 2020-09-30 Abbott Diabetes Care Inc. Procédé et appareil permettant de déterminer le début du repas et le pic prandial dans des systèmes de surveillance d'analyte
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3050023B1 (fr) 2014-10-27 2021-08-25 Aseko, Inc. Gestion sous-cutanée de patient externe
CN107708581B (zh) 2015-06-10 2021-11-19 Ekos公司 超声波导管
CN108024765B (zh) 2015-07-10 2021-06-11 雅培糖尿病护理公司 对于生理参数进行动态葡萄糖曲线响应的系统、装置和方法
WO2017027432A1 (fr) 2015-08-07 2017-02-16 Aptima, Inc. Systèmes et procédés d'aide à la décision de thérapie médicale
WO2017031440A1 (fr) 2015-08-20 2017-02-23 Aseko, Inc. Conseiller de thérapie pour la gestion du diabète
US10575790B2 (en) * 2016-03-02 2020-03-03 Roche Diabetes Care, Inc. Patient diabetes monitoring system with clustering of unsupervised daily CGM profiles (or insulin profiles) and method thereof
EP3223181B1 (fr) 2016-03-24 2019-12-18 Sofradim Production Système et procédé de génération d'un modèle et de simulation d'un effet sur un site de réparation chirurgicale
US10052073B2 (en) 2016-05-02 2018-08-21 Dexcom, Inc. System and method for providing alerts optimized for a user
CA3029272A1 (fr) 2016-09-09 2018-03-15 Dexcom, Inc. Systemes et procedes pour calculateur de bolus a base de cgm pour affichage et pour la fourniture a des dispositifs d'administration de medicament
US10783801B1 (en) 2016-12-21 2020-09-22 Aptima, Inc. Simulation based training system for measurement of team cognitive load to automatically customize simulation content
WO2018175489A1 (fr) 2017-03-21 2018-09-27 Abbott Diabetes Care Inc. Méthodes, dispositifs et système pour fournir un diagnostic et une thérapie pour un état diabétique
EP3642789A4 (fr) * 2017-06-20 2021-01-27 Chan, Sidney Soong-Ling Procédé et système de surveillance d'un plan de traitement du diabète à
US11116898B2 (en) 2017-06-26 2021-09-14 Abbott Diabetes Care Inc. Artificial pancreas integrated CGM architectures and designs
CN212438615U (zh) 2017-10-24 2021-02-02 德克斯康公司 可穿戴设备
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11076531B2 (en) 2018-01-23 2021-08-03 Deere & Company State machine for multiple input-multiple output harvester control
CN111655128A (zh) 2018-02-09 2020-09-11 德克斯康公司 用于决策支持的系统和方法
KR102035644B1 (ko) * 2018-07-09 2019-10-23 주식회사 필로시스 혈당 단위를 자동으로 결정하는 혈당 측정 장치 및 방법
RU2707064C1 (ru) * 2019-02-12 2019-11-21 Общество с ограниченной ответственностью "Гардлайнер" Система для сравнения гликемических профилей у больных сахарным диабетом
US11804289B2 (en) * 2019-12-18 2023-10-31 Dexcom, Inc. Therapeutic zone assessor
CN112233780B (zh) * 2020-09-25 2022-08-05 福州康为网络技术有限公司 一种糖尿病管理系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5971922A (en) 1998-04-07 1999-10-26 Meidensha Electric Mfg Co Ltd System and method for predicting blood glucose level

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8413830D0 (en) * 1984-05-31 1984-07-04 Seltronix Ltd Blood glucose monitor
JPS6125525A (ja) * 1984-07-13 1986-02-04 住友電気工業株式会社 患者監視装置
US4695954A (en) * 1984-10-31 1987-09-22 Rose Robert J Modular medication dispensing system and apparatus utilizing portable memory device
US5206144A (en) * 1985-03-29 1993-04-27 Novo Industri A/S Determination of glycated (glycosylated) hemoglobin in blood
US4731726A (en) * 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
EP0290683A3 (fr) * 1987-05-01 1988-12-14 Diva Medical Systems B.V. Système et appareil de contrôle médical du diabète
US5216597A (en) * 1987-05-01 1993-06-01 Diva Medical Systems Bv Diabetes therapy management system, apparatus and method
US4817044A (en) * 1987-06-01 1989-03-28 Ogren David A Collection and reporting system for medical appliances
CA1338348C (fr) * 1987-11-30 1996-05-28 Kazutoshi Yamazaki Agent d'elimination pour hemoglobine glycosylee
US5025374A (en) * 1987-12-09 1991-06-18 Arch Development Corp. Portable system for choosing pre-operative patient test
WO1989006989A1 (fr) * 1988-01-29 1989-08-10 The Regents Of The University Of California Distributeur ou echantillonneur iontophoretique non-invasif
US5108564A (en) * 1988-03-15 1992-04-28 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5128015A (en) * 1988-03-15 1992-07-07 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5076273A (en) * 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US4975581A (en) * 1989-06-21 1990-12-04 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
CA2028261C (fr) * 1989-10-28 1995-01-17 Won Suck Yang Methode et appareil non effractifs pour mesurer le taux de glycemie
US5140985A (en) * 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5036861A (en) * 1990-01-11 1991-08-06 Sembrowich Walter L Method and apparatus for non-invasively monitoring plasma glucose levels
IL98203A (en) 1990-06-20 1996-06-18 Bayer Ag A moving electronic log and a method for storing and viewing data
EP0550517B1 (fr) * 1990-08-31 1998-12-23 The General Hospital Corporation Systeme pour administrer plusieurs dispositifs, par exemple des dispositifs portables de controle d'un malade dans un reseau
US5251126A (en) * 1990-10-29 1993-10-05 Miles Inc. Diabetes data analysis and interpretation method
US5376070A (en) * 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US5997476A (en) * 1997-03-28 1999-12-07 Health Hero Network, Inc. Networked system for interactive communication and remote monitoring of individuals
US5307263A (en) * 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US5960403A (en) * 1992-11-17 1999-09-28 Health Hero Network Health management process control system
US5590648A (en) * 1992-11-30 1997-01-07 Tremont Medical Personal health care system
AU2984892A (en) * 1992-12-02 1994-06-16 Japanic Corporation Raw sewage disposal apparatus
FI95427C (fi) * 1992-12-23 1996-01-25 Instrumentarium Oy Tiedonsiirtojärjestelmä
US5558638A (en) * 1993-04-30 1996-09-24 Healthdyne, Inc. Patient monitor and support system
US6206829B1 (en) * 1996-07-12 2001-03-27 First Opinion Corporation Computerized medical diagnostic and treatment advice system including network access
US6022315A (en) * 1993-12-29 2000-02-08 First Opinion Corporation Computerized medical diagnostic and treatment advice system including network access
US5553615A (en) * 1994-01-31 1996-09-10 Minnesota Mining And Manufacturing Company Method and apparatus for noninvasive prediction of hematocrit
US5748851A (en) * 1994-02-28 1998-05-05 Kabushiki Kaisha Meidensha Method and apparatus for executing short-term prediction of timeseries data
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5704366A (en) * 1994-05-23 1998-01-06 Enact Health Management Systems System for monitoring and reporting medical measurements
WO1996000110A1 (fr) 1994-06-24 1996-01-04 Cygnus, Inc. Dispositif et procede pour le prelevement d'echantillons par iontophorese
US5431793A (en) * 1994-07-29 1995-07-11 Beckman Instruments, Inc. Quantitative analysis of glycosylated hemoglobin by immunocappillary electrophoresis
JP3150857B2 (ja) * 1994-10-19 2001-03-26 富士写真フイルム株式会社 グリコヘモグロビン含有比測定用分析要素及び分析方法
US5946659A (en) * 1995-02-28 1999-08-31 Clinicomp International, Inc. System and method for notification and access of patient care information being simultaneously entered
US5713856A (en) * 1995-03-13 1998-02-03 Alaris Medical Systems, Inc. Modular patient care system
AU5530996A (en) * 1995-03-31 1996-10-16 Michael W. Cox System and method of generating prognosis reports for corona ry health management
US5695949A (en) * 1995-04-07 1997-12-09 Lxn Corp. Combined assay for current glucose level and intermediate or long-term glycemic control
US6671563B1 (en) * 1995-05-15 2003-12-30 Alaris Medical Systems, Inc. System and method for collecting data and managing patient care
US5989409A (en) * 1995-09-11 1999-11-23 Cygnus, Inc. Method for glucose sensing
US5741211A (en) * 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
FI960636A (fi) * 1996-02-12 1997-08-13 Nokia Mobile Phones Ltd Menetelmä potilaan terveydentilan valvomiseksi
FI118509B (fi) * 1996-02-12 2007-12-14 Nokia Oyj Menetelmä ja laitteisto potilaan veren glukoosipitoisuuden ennustamiseksi
US5974389A (en) * 1996-03-01 1999-10-26 Clark; Melanie Ann Medical record management system and process with improved workflow features
US5801057A (en) * 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction
US5878384A (en) * 1996-03-29 1999-03-02 At&T Corp System and method for monitoring information flow and performing data collection
US5822935A (en) * 1996-12-19 1998-10-20 Steelcase Inc. Solid-core wall system
US5959529A (en) * 1997-03-07 1999-09-28 Kail, Iv; Karl A. Reprogrammable remote sensor monitoring system
US6234964B1 (en) * 1997-03-13 2001-05-22 First Opinion Corporation Disease management system and method
US6270455B1 (en) * 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
FI112545B (fi) * 1997-05-30 2003-12-15 Nokia Corp Menetelmä ja järjestelmä potilaan veren glykosyloidun hemoglobiinikomponentin tason ennustamiseksi
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6054039A (en) * 1997-08-18 2000-04-25 Shieh; Paul Determination of glycoprotein and glycosylated hemoglobin in blood
US5997475A (en) * 1997-08-18 1999-12-07 Solefound, Inc. Device for diabetes management
EP0910023A2 (fr) * 1997-10-17 1999-04-21 Siemens Aktiengesellschaft Méthode et dispositif pour le modélisation neuromimétique d'un système dynamique avec un comportement non-linéaire stochastique
EP1025530A2 (fr) * 1997-10-31 2000-08-09 Amira Medical Systeme servant a recueillir et a communiquer des informations concernant la concentration d'une substance a analyser
US6144922A (en) * 1997-10-31 2000-11-07 Mercury Diagnostics, Incorporated Analyte concentration information collection and communication system
US6049764A (en) * 1997-11-12 2000-04-11 City Of Hope Method and system for real-time control of analytical and diagnostic instruments
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6024699A (en) * 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6579231B1 (en) * 1998-03-27 2003-06-17 Mci Communications Corporation Personal medical monitoring unit and system
EP1068568A4 (fr) * 1998-04-03 2004-10-27 Triangle Pharmaceuticals Inc SYSTEMES, PROCEDES ET PRODUITS DE PROGRAMMES INFORMATIQUES DESTINES A GUIDER LA SELECTION DE SCHEMAS THERAPEUTIQUES$i( )
US8974386B2 (en) * 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
DK1077636T3 (da) * 1998-05-13 2004-05-24 Cygnus Therapeutic Systems Signalbehandling til måling af fysiologiske analytter
DE69910003T2 (de) * 1998-05-13 2004-04-22 Cygnus, Inc., Redwood City Überwachung physiologischer analyte
GB9812432D0 (en) * 1998-06-09 1998-08-05 Queen Mary & Westfield College Predictive test
US7384396B2 (en) * 1998-07-21 2008-06-10 Spectrx Inc. System and method for continuous analyte monitoring
US6338713B1 (en) * 1998-08-18 2002-01-15 Aspect Medical Systems, Inc. System and method for facilitating clinical decision making
US6554798B1 (en) * 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
JP2000060803A (ja) * 1998-08-21 2000-02-29 Terumo Corp 血糖値情報処理システム
WO2000018289A1 (fr) 1998-09-30 2000-04-06 Cygnus, Inc. Procede et dispositif de prediction de valeurs physiologiques
US6201980B1 (en) 1998-10-05 2001-03-13 The Regents Of The University Of California Implantable medical sensor system
US6540672B1 (en) * 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
CA2352295C (fr) * 1998-11-30 2008-07-15 Novo Nordisk A/S Procede et systeme permettant a un utilisateur de s'administrer seul son traitement medical, ledit traitement medical comprenant plusieurs actes
US6422061B1 (en) * 1999-03-03 2002-07-23 Cyrano Sciences, Inc. Apparatus, systems and methods for detecting and transmitting sensory data over a computer network
WO2000057774A1 (fr) * 1999-03-29 2000-10-05 Avocet Medical, Inc. Compteur avec base de donnees integree et capacite de telemedecine simplifiee
US6336900B1 (en) * 1999-04-12 2002-01-08 Agilent Technologies, Inc. Home hub for reporting patient health parameters
US6277071B1 (en) * 1999-06-25 2001-08-21 Delphi Health Systems, Inc. Chronic disease monitor
US6804558B2 (en) * 1999-07-07 2004-10-12 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US6611846B1 (en) * 1999-10-30 2003-08-26 Medtamic Holdings Method and system for medical patient data analysis
US6406426B1 (en) * 1999-11-03 2002-06-18 Criticare Systems Medical monitoring and alert system for use with therapeutic devices
US6418346B1 (en) * 1999-12-14 2002-07-09 Medtronic, Inc. Apparatus and method for remote therapy and diagnosis in medical devices via interface systems
US6692436B1 (en) * 2000-04-14 2004-02-17 Computerized Screening, Inc. Health care information system
AU6465401A (en) * 2000-05-19 2001-12-03 Welch Allyn Protocol Inc Patient monitoring system
CA2349021C (fr) * 2000-06-16 2010-03-30 Bayer Corporation Systeme, methode et appareil biocapteur permettant la transmission de donnees a l'aide d'un assistant numerique personnel
LV12612B (lv) * 2000-08-21 2001-03-20 Jehezkelis FINKELŠTEINS Medicīniski-bioloģiskas informācijas vākšanas un apstrādes metode un sistēma
US6450956B1 (en) * 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
US6524240B1 (en) * 2000-11-22 2003-02-25 Medwave, Inc. Docking station for portable medical devices
US6645142B2 (en) * 2000-12-01 2003-11-11 Optiscan Biomedical Corporation Glucose monitoring instrument having network connectivity
US6799149B2 (en) * 2000-12-29 2004-09-28 Medtronic, Inc. Therapy management techniques for an implantable medical device
US6551243B2 (en) * 2001-01-24 2003-04-22 Siemens Medical Solutions Health Services Corporation System and user interface for use in providing medical information and health care delivery support
US20060106644A1 (en) * 2001-05-30 2006-05-18 Koo Charles C Patient referral and physician-to-physician marketing method and system
US6544212B2 (en) * 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US6781522B2 (en) * 2001-08-22 2004-08-24 Kivalo, Inc. Portable storage case for housing a medical monitoring device and an associated method for communicating therewith
US20030216628A1 (en) * 2002-01-28 2003-11-20 Bortz Jonathan David Methods and systems for assessing glycemic control using predetermined pattern label analysis of blood glucose readings
US20050187789A1 (en) * 2004-02-25 2005-08-25 Cardiac Pacemakers, Inc. Advanced patient and medication therapy management system and method
US20050267780A1 (en) * 2004-06-01 2005-12-01 Pinaki Ray Methods and systems of automating medical device data management
WO2005119524A2 (fr) * 2004-06-04 2005-12-15 Therasense, Inc. Architecture hote-client de soins pour le diabete et systemes de gestion de donnees
US20060173260A1 (en) * 2005-01-31 2006-08-03 Gmms Ltd System, device and method for diabetes treatment and monitoring
US20070033074A1 (en) * 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5971922A (en) 1998-04-07 1999-10-26 Meidensha Electric Mfg Co Ltd System and method for predicting blood glucose level

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065033A3 (fr) * 2002-01-28 2004-02-05 Control Diabetes Inc Procedes et systemes permettant d'evaluer le controle de glycemie par une analyse d'une etiquette de schema predeterminee des valeurs mesurees de glycemie
WO2003065033A2 (fr) * 2002-01-28 2003-08-07 Control Diabetes, Inc. Procedes et systemes permettant d'evaluer le controle de glycemie par une analyse d'une etiquette de schema predeterminee des valeurs mesurees de glycemie
EP2327359A1 (fr) 2002-08-13 2011-06-01 University Of Virginia Patent Foundation Procédé, système et produit de programme informatique pour le traitment de données d'autosurveillance de glycémie (SMBG) permettant d'améliorer une autogestion diabétique
WO2004015539A2 (fr) 2002-08-13 2004-02-19 University Of Virginia Patent Foundation Procede, systeme et produit de programme informatique pour le traitement de donnees d'autosurveillance de glycemie (smbg) permettant d'ameliorer une autogestion diabetique
US8538703B2 (en) 2002-08-13 2013-09-17 University Of Virginia Patent Foundation Method, system, and computer program product for the processing of self-monitoring blood glucose(SMBG)data to enhance diabetic self-management
EP1534121A4 (fr) * 2002-08-13 2008-12-10 Univ Virginia Procede, systeme et produit de programme informatique pour le traitement de donnees d'autosurveillance de glycemie (smbg) permettant d'ameliorer une autogestion diabetique
EP1534121A2 (fr) * 2002-08-13 2005-06-01 University Of Virginia Patent Foundation Procede, systeme et produit de programme informatique pour le traitement de donnees d'autosurveillance de glycemie (smbg) permettant d'ameliorer une autogestion diabetique
JP2005535885A (ja) * 2002-08-13 2005-11-24 ユニヴァースティ オブ ヴァージニア パテント ファウンデイション 糖尿病自己管理を推進するための自己モニタリング血糖（ｓｍｂｇ）データを処理するための方法、システムおよびコンピュータ・プログラム・プロダクト
EP2322092A1 (fr) 2002-08-13 2011-05-18 University Of Virginia Patent Foundation Procédé, système et produit de programme informatique permettant de traiter les données de glucose sanguin à auto-surveillance pour améliorer la gestion automatique diabétique
JP2004154563A (ja) * 2002-10-08 2004-06-03 Bayer Healthcare Llc 患者の診断及び治療におけるデータ管理のための方法及びシステム
EP1416417A3 (fr) * 2002-10-08 2007-03-07 Bayer HealthCare LLC Procédé et systèmes pour le traitement de données de diagnostic et de traitement de patients
EP1416417A2 (fr) * 2002-10-08 2004-05-06 Bayer Healthcare, LLC Procédé et systèmes pour le traitement de données de diagnostic et de traitement de patients
US7266400B2 (en) 2003-05-06 2007-09-04 Orsense Ltd. Glucose level control method and system
US10524669B2 (en) 2003-10-13 2020-01-07 Novo Nordisk A/S Apparatus and method for determining a physiological condition
US7914449B2 (en) 2004-03-17 2011-03-29 Sysmex Corporation Diagnostic support system for diabetes and storage medium
US7815569B2 (en) 2004-04-21 2010-10-19 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
US9501949B2 (en) 2004-10-07 2016-11-22 Novo Nordisk A/S Method and system for self-management of a disease
WO2006050980A3 (fr) * 2004-11-15 2006-08-31 Novo Nordisk As Procede et appareil permettant de surveiller des effets a long et court termes d'un traitement
WO2006050980A2 (fr) * 2004-11-15 2006-05-18 Novo Nordisk A/S Procede et appareil permettant de surveiller des effets a long et court termes d'un traitement
US11355238B2 (en) 2006-01-05 2022-06-07 University Of Virginia Patent Foundation Method, system and computer program product for evaluation of blood glucose variability in diabetes from self-monitoring data
EP1988821A4 (fr) * 2006-01-05 2010-08-25 Univ Virginia Méthode, système et programme informatique d'évaluation des variations de la glycémie chez les diabétiques, à partir de donné d'auto-contrôle
JP2009523230A (ja) * 2006-01-05 2009-06-18 ユニバーシティ オブ バージニア パテント ファウンデーション 自己監視データから糖尿病における血糖変動性を評価するための方法、装置及びコンピュータ・プログラム・プロダクト
EP1988821A2 (fr) * 2006-01-05 2008-11-12 University Of Virginia Patent Foundation Méthode, système et programme informatique d'évaluation des variations de la glycémie chez les diabétiques, à partir de donné d'auto-contrôle
WO2007081853A2 (fr) 2006-01-05 2007-07-19 University Of Virginia Patent Foundation Méthode, système et programme informatique d’évaluation des variations de la glycémie chez les diabétiques, à partir de donné d'auto-contrôle
EP2535831A1 (fr) 2006-03-31 2012-12-19 Lifescan, Inc. Procédés et systèmes de gestion du diabète
EP3544017A1 (fr) 2006-03-31 2019-09-25 Lifescan, Inc. Procédés et systèmes de gestion du diabète
US7824333B2 (en) 2006-03-31 2010-11-02 Lifescan, Inc. Diabetes management methods and systems
EP1956371A2 (fr) 2006-12-21 2008-08-13 Lifescan, Inc. Systèmes, procédés et codes de programme informatique pour reconnaissance de motifs d'hyperglycémie et d'hypoglycémie, variabilité de glucose augmentée, et auto-surveillance inefficace pour les diabètes
WO2010077330A1 (fr) * 2008-12-31 2010-07-08 Medtronic Minimed, Inc. Procédé et/ou système d'estimation du taux d'hémoglobine glyquée
EP2218394A1 (fr) * 2009-02-17 2010-08-18 Clifton A. Alferness Système et procédé pour fournir un outil personnalisé pour évaluer l'hémoglobine glyquée
US11751779B2 (en) 2009-02-25 2023-09-12 University Of Virginia Patent Foundation Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery
US11723562B2 (en) * 2009-02-25 2023-08-15 University Of Virginia Patent Foundation Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery
US20210038132A1 (en) * 2009-02-25 2021-02-11 University Of Virginia Patent Foundation Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery
US10420489B2 (en) 2009-05-29 2019-09-24 University Of Virginia Patent Foundation System coordinator and modular architecture for open-loop and closed-loop control of diabetes
EP3841968A1 (fr) 2010-03-26 2021-06-30 The University of Virginia Patent Foundation Procédé, système et produit-programme d'ordinateur permettant d'améliorer la précision des capteurs de glucose utilisant l'observation de la délivrance d'insuline dans le diabète
EP4183326A1 (fr) 2010-03-26 2023-05-24 University Of Virginia Patent Foundation Procédé, système et produit de programme informatique pour améliorer la précision de capteurs de glucose à l'aide d'observation de l'administration d'insuline dans le diabète
EP3593711A1 (fr) 2010-03-26 2020-01-15 The University of Virginia Patent Foundation Procédé, système et produit-programme d'ordinateur permettant d'améliorer la précision des capteurs de glucose utilisant l'observation de la délivrance d'insuline dans le diabète
US10610154B2 (en) 2011-06-23 2020-04-07 University Of Virginia Patent Foundation Unified platform for monitoring and control of blood glucose levels in diabetic patients
EP3799073A1 (fr) 2011-08-26 2021-03-31 The University of Virginia Patent Foundation Procédé, système et support lisible par ordinateur pour la régulation adaptative conseillée du diabète
WO2013073983A1 (fr) * 2011-11-16 2013-05-23 Vengerov Yury Yuzefovitch Dispositif de lecture de résultats d'analyses réalisées à l'aide d'une languette de test
CN104470430A (zh) * 2012-07-19 2015-03-25 生命扫描有限公司 指示糖尿病人群高血糖或低血糖的方法和系统
US8768673B2 (en) 2012-07-26 2014-07-01 Rimidi Diabetes, Inc. Computer-implemented system and method for improving glucose management through cloud-based modeling of circadian profiles
US8756043B2 (en) 2012-07-26 2014-06-17 Rimidi Diabetes, Inc. Blood glucose meter and computer-implemented method for improving glucose management through modeling of circadian profiles
US8744828B2 (en) 2012-07-26 2014-06-03 Rimidi Diabetes, Inc. Computer-implemented system and method for improving glucose management through modeling of circadian profiles
US10881334B2 (en) 2014-08-14 2021-01-05 University Of Virginia Patent Foundation Accuracy continuous glucose monitoring method, system, and device
WO2016093684A1 (fr) * 2014-12-09 2016-06-16 Instituto Superior Autónomo De Occidente A.C. Appareil électronique portable émettant des suggestions sur des activités ou des événements influençant un état d'intérêt pour un individu
US11311665B2 (en) 2015-06-09 2022-04-26 University Of Virginia Patent Foundation Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking
US10463789B2 (en) 2015-09-02 2019-11-05 University Of Virginia Patent Foundation System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users
RU2746830C1 (ru) * 2020-06-01 2021-04-21 Федеральное государственное бюджетное научное учреждение Федеральный исследовательский центр "Институт цитологии и генетики Сибирского отделения Российской академии наук" (ИЦиГ СО РАН) Способ оценки вариабельности гликемии для определения эффективности проводимой сахароснижающей терапии у пациентов с MODY2 диабетом
WO2022199765A1 (fr) * 2021-03-22 2022-09-29 Eyesense Gmbh Procédé pour déterminer une valeur instantanée de glucose dans un fluide de transport

Also Published As

Publication number Publication date
EP1267708A2 (fr) 2003-01-02
CN1422136A (zh) 2003-06-04
MXPA02009487A (es) 2003-03-10
IL151720A (en) 2007-10-31
CN100448392C (zh) 2009-01-07
IL151720A0 (en) 2003-04-10
PL357511A1 (en) 2004-07-26
JP2003528330A (ja) 2003-09-24
PL198154B1 (pl) 2008-05-30
DZ3338A1 (fr) 2001-10-04
IL183273A0 (en) 2007-09-20
US20120004512A1 (en) 2012-01-05
RU2283495C2 (ru) 2006-09-10
KR20020092405A (ko) 2002-12-11
US7025425B2 (en) 2006-04-11
US20030212317A1 (en) 2003-11-13
JP4891511B2 (ja) 2012-03-07
AU2001251046B2 (en) 2006-08-03
EP1267708A4 (fr) 2006-04-12
KR100776070B1 (ko) 2007-11-16
US7874985B2 (en) 2011-01-25
CA2404262C (fr) 2009-03-24
US20060094947A1 (en) 2006-05-04
CA2404262A1 (fr) 2001-10-04
WO2001072208A3 (fr) 2002-03-07
AU5104601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
CA2404262C (fr) Procede, systeme et produit informatique ameliorant l'exploitation des donnees de glycemie obtenues par auto-controle
AU2001251046A1 (en) Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US9317657B2 (en) Method, system, and computer program product for tracking of blood glucose variability in diabetes
US10019554B2 (en) Glycemic risk determination based on variability of glucose
US11355238B2 (en) Method, system and computer program product for evaluation of blood glucose variability in diabetes from self-monitoring data
CA2615575C (fr) Systemes, methodes et produits de programme informatique servant a la reconnaissance de recurrences d'hyperglycemie chez un utilisateur
EP2322092B1 (fr) Procédé, système et produit de programme informatique permettant de traiter les données de glucose sanguin à auto-surveillance pour améliorer la gestion automatique diabétique
AU2017420200A1 (en) Method and system for monitoring a diabetes treatment plan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001251046

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 151720

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2404262

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/1539/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10240228

Country of ref document: US

Ref document number: PV2002-3232

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2001 570172

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027012856

Country of ref document: KR

Ref document number: PA/a/2002/009487

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018075541

Country of ref document: CN

REEP Request for entry into the european phase

Ref document number: 2001924388

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001924388

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002128925

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027012856

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001924388

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3232

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 183273

Country of ref document: IL